Furong Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Furong Qiu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Fengyi Weng
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
2 shared publicationsGuochao Song
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
2 shared publications- Yue Li
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
2 shared publications Bin Zou
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New District, Shanghai 201213, China
1 shared publication- Bin Zou
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
1 shared publication Cheng-Hai Liu
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New District, Shanghai 201213, China
1 shared publication
Latest Publications
- 20 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176193
Glycyrrhetinic acid attenuates endoplasmic reticulum stress-induced hepatocyte apoptosis via CHOP/DR5/Caspase 8 pathway in cholestasis
- 20 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176193
Glycyrrhetinic acid attenuates endoplasmic reticulum stress-induced hepatocyte apoptosis via CHOP/DR5/Caspase 8 pathway in cholestasis
- Open Access
- 13 April 2023
- Published by Portland Press Ltd. in Clinical Science
- Vol. 137 (7) , 561-577
Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway
Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employed to treat hepatobiliary disorders and is as effective as UDCA in alleviating cholestatic liver disease in clinical trials. Until now, TUDCA’s mechanism of action towards cholestasis remains unclear. In this study, cholestasis was induced with a cholic acid (CA)-supplemented diet or alpha-naphthyl isothiocyanate (ANIT) gavage in wild-type and Farnesoid X Receptor (FXR) deficient mice, using obeticholic acid (OCA) as control. The effects of TUDCA on liver histological changes, transaminase level, bile acid composition, hepatocyte death, expression of Fxr and Nuclear factor erythroid 2-related factor 2 (Nrf2) and target genes, as well as apoptotic signaling pathways, were investigated. Treating CA-fed mice with TUDCA markedly alleviated liver injury, attenuated bile acids retention in liver and plasma, increased Fxr and Nrf2 nuclear levels and modulated the expression of targets regulating synthesis and transportation of bile acids, including BSEP, MRP2, NTCP and CYP7A1. TUDCA, but not OCA, activated Nrf2 signaling and exerted protective effects against cholestatic liver injury in Fxr-/- mice fed with CA. Furthermore, in both mice with CA- and ANIT-induced cholestasis, TUDCA decreased expression of GRP78 and CCAAT/enhancer-binding protein homologous protein (CHOP); reduced Death Receptor 5 (DR5) transcription, caspase-8 activation, and BID cleavage; and subsequently inhibited activation of executioner caspases and apoptosis in liver. We confirmed that TUDCA protected against cholestatic liver injury by alleviating BAs burden of dually activating hepatic Fxr and Nrf2. Moreover, inhibiting CHOP-DR5-caspase-8 pathway contributed to the anti-apoptotic effect of TUDCA in cholestasis.
- 13 April 2023
- Published by Portland Press Ltd. in Clinical Science
- Vol. 137 (7) , 561-577
Open AccessPotential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway
Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employed to treat hepatobiliary disorders and is as effective as UDCA in alleviating cholestatic liver disease in clinical trials. Until now, TUDCA’s mechanism of action towards cholestasis remains unclear. In this study, cholestasis was induced with a cholic acid (CA)-supplemented diet or alpha-naphthyl isothiocyanate (ANIT) gavage in wild-type and Farnesoid X Receptor (FXR) deficient mice, using obeticholic acid (OCA) as control. The effects of TUDCA on liver histological changes, transaminase level, bile acid composition, hepatocyte death, expression of Fxr and Nuclear factor erythroid 2-related factor 2 (Nrf2) and target genes, as well as apoptotic signaling pathways, were investigated. Treating CA-fed mice with TUDCA markedly alleviated liver injury, attenuated bile acids retention in liver and plasma, increased Fxr and Nrf2 nuclear levels and modulated the expression of targets regulating synthesis and transportation of bile acids, including BSEP, MRP2, NTCP and CYP7A1. TUDCA, but not OCA, activated Nrf2 signaling and exerted protective effects against cholestatic liver injury in Fxr-/- mice fed with CA. Furthermore, in both mice with CA- and ANIT-induced cholestasis, TUDCA decreased expression of GRP78 and CCAAT/enhancer-binding protein homologous protein (CHOP); reduced Death Receptor 5 (DR5) transcription, caspase-8 activation, and BID cleavage; and subsequently inhibited activation of executioner caspases and apoptosis in liver. We confirmed that TUDCA protected against cholestatic liver injury by alleviating BAs burden of dually activating hepatic Fxr and Nrf2. Moreover, inhibiting CHOP-DR5-caspase-8 pathway contributed to the anti-apoptotic effect of TUDCA in cholestasis.
- 22 August 2005
- Published by Wiley in Magnetic Resonance in Chemistry
- Vol. 43 (11) , 918-925
ESR spin‐label study of poly(styrene‐co‐methacrylic acid)/poly(ε‐caprolactone) semi‐interpenetrating polymer networks with controlled hydrogen‐bond interactions
The morphology and miscibility of semi‐interpenetrating polymer networks (semi‐IPN) prepared with poly(styrene‐co‐methacrylic acid) [P(S‐co‐MAA)] of different carboxylic acid contents and poly(ε‐caprolactone) (PCL) have been studied by ESR spin‐label method. The ESR spectra of spin‐labeled PCL showed one motional component at any specific temperature. It indicated that the spin‐labeled molecules were located in one type of environment. The coexistence of two motional components in the ESR spectra of all semi‐IPN samples was observed over a certain temperature range. This phenomenon suggested that the semi‐IPNs were not compatible systems; they contained two microphases, a PCL‐rich microdomain and a P(S‐co‐MAA)‐rich microdomain. The miscibility could be improved by increasing the carboxylic acid content, which could enhance the hydrogen‐bonding interactions between the ester groups of PCL and carboxylic acid groups in P(S‐co‐MAA). It was also found that the intracomponent cross‐linking of the semi‐IPNs was not in favor of the miscibility. The microphase separation occurred in all semi‐IPNs, even in the samples having strong hydrogen‐bonding interactions. With increasing cross‐linking density, the microphase separation became more remarkable. Copyright © 2005 John Wiley & Sons, Ltd.
- 22 August 2005
- Published by Wiley in Magnetic Resonance in Chemistry
- Vol. 43 (11) , 918-925
ESR spin‐label study of poly(styrene‐co‐methacrylic acid)/poly(ε‐caprolactone) semi‐interpenetrating polymer networks with controlled hydrogen‐bond interactions
The morphology and miscibility of semi‐interpenetrating polymer networks (semi‐IPN) prepared with poly(styrene‐co‐methacrylic acid) [P(S‐co‐MAA)] of different carboxylic acid contents and poly(ε‐caprolactone) (PCL) have been studied by ESR spin‐label method. The ESR spectra of spin‐labeled PCL showed one motional component at any specific temperature. It indicated that the spin‐labeled molecules were located in one type of environment. The coexistence of two motional components in the ESR spectra of all semi‐IPN samples was observed over a certain temperature range. This phenomenon suggested that the semi‐IPNs were not compatible systems; they contained two microphases, a PCL‐rich microdomain and a P(S‐co‐MAA)‐rich microdomain. The miscibility could be improved by increasing the carboxylic acid content, which could enhance the hydrogen‐bonding interactions between the ester groups of PCL and carboxylic acid groups in P(S‐co‐MAA). It was also found that the intracomponent cross‐linking of the semi‐IPNs was not in favor of the miscibility. The microphase separation occurred in all semi‐IPNs, even in the samples having strong hydrogen‐bonding interactions. With increasing cross‐linking density, the microphase separation became more remarkable. Copyright © 2005 John Wiley & Sons, Ltd.